Nuvectis Pharma, Inc. (NVCT): Cash & Equivalents
$31.63M
As of 2025-12-31
$22.16M
As of 2026-06-30
+16.5%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.63M | +70.7% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $18.53M | -3.1% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $19.13M | -4.3% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $19.99M | +248.2% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $5.74M | n/a | 2023-03-08, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $31.63M | +70.7% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $12.64M | +531.6% |
| Equillium, Inc. (EQ) | 2025-12-31 | $30.28M | +67.4% |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $20.73M | -34.4% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $345.1K | -44.9% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $26.71M | -35.9% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $24.03M | +20.6% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
Compare NVCT, VBIO, EQ, TVRD side by side · Screen every company in Pharmaceutical Preparations ↗